Jinlan Gene Co-Founder and General Manager Dong Xiaoyan: An Analysis of Key Elements for the Development of China's Gene Therapy Industry
Genecradle
Gene Therapy Drug Developer
On September 4–5, 2026, the CBI2026 Biopharmaceutical Innovation Expo will open at Hall B of the Suzhou International Expo Center. This conference has the honor of inviting[Genecradle, Co-Founder and General Manager Dong Xiaoyan]Attended the CGT Therapy Innovation Conference in Hall B, Room 101, to deliver a keynote presentation.【[A Brief Analysis of the Key Elements for the Development of China's Gene Therapy Industry]
With 33 years of experience in the viral vector/gene therapy industry. Involved in over 30 inventions, such as: HSV1-rc/AAV system; AAV8-HBV1.3 mouse hepatitis B model, an important platform for new drug development against hepatitis B; AAV reverse infection technique; real-time dynamic detection technology for miRNA activity profiles in living cells.
Executive Director of the China Biopharmaceutical Industry Chain Innovation and Translation Consortium; Chairperson of the Gene Therapy Committee
China Pharmaceutical Quality Management Association, Professional Committee for Quality Research of Cell and Gene Therapy Drugs, Vice Chair;
Editorial Board Member of Progress in Pharmaceutical Sciences;
Member of the Editorial Committee of Chinese Journal of Medical Guide;
Zhongguancun High-End Leading Talent, Economic Development Zone “Yi Qilin” Leading Talent, Daxing District “New Gateway” Leading Talent.
Forum Name:CBI 2026 Innovative CGT Therapy Conference
Forum Time:September 4–5, 2026
Forum Venue:Suzhou International Expo Center, Hall B, Booth B101
Development of Next-Generation Immune Cell Therapies
Latest Research Advances in In Vivo CAR-T
Next-Generation In Vivo CAR-T Cell Therapy
Research and Application of Novel CAR-T Cells
Current Status and Prospects of Universal CAR-T Development in the Autoimmune Disease Field
Clinical Development Progress of CAR-T Cell Therapy
Current Commercialization Status and Future of CAR-T Cell Therapy
Challenges in Process Development and Quality Management
CAR-T Therapy for Autoimmune Diseases of the Nervous System
Advances in the Development of Cell Therapies for Solid Tumors
Large-Scale Preparation and Application of Stem Cell-Derived Exosomes
Development Strategies for Exosomes as Nucleic Acid Drug Delivery Vehicles
Quality Control and Regulatory Considerations for the Large-Scale Production of Exosomes
Design and Engineering Strategies for Exosomes
Exploration of Exosomes in Tumor Immunotherapy
Application Prospects of Exosomes in Regenerative Medicine and Anti-Aging
Advances in Stem Cell Therapy for Cancer Treatment
Development Strategies for iPSC-Derived Cell Therapeutics
Non-Clinical Evaluation Strategy for iPSC-Derived Cell Products
Research and Development Progress of iPSC-Derived Cell Therapy Products in the Treatment of Neurological Diseases
Specifications for the Production and Quality Control of Cell-Based Pharmaceutical Products
iPSC-Derived Cell Therapy: Process and Clinical Breakthroughs
iPSC-Derived Cell Products for the Treatment of Neurological Disorders
Development Prospects and Applications of AAV Gene Therapy Drugs
Research and Development Progress of AAV in Central Nervous System Diseases
Gene Therapy Development Strategies in the Field of Rare Diseases
Innovative Development of Ophthalmic Gene Therapy Drugs
AAV Gene Therapy Product Development
The Path to Innovation and Commercialization of Gene Therapy Drugs
Development of AAV Gene Delivery Tools
Registration:
ConferenceLimited-Time Free Access(Limited spots, first-come-first-served. This registration is a pre-registration; registration is considered successful only after approval.) Accommodation and meals are at the participant's own expense.
For business cooperation inquiries regarding exhibition participation, sponsorship, co-organization, etc., please feel free to contact us:
Business Cooperation:CMC Pharma Expo 400-1662-808
Conference Inquiry:Ms. Li 18215607723 (WeChat ID same as phone number)